Meritage Portfolio Management Purchases 36,000 Shares of CalciMedica, Inc. (NASDAQ:CALC)

Meritage Portfolio Management lifted its holdings in shares of CalciMedica, Inc. (NASDAQ:CALC) by 360.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 46,000 shares of the company’s stock after purchasing an additional 36,000 shares during the period. Meritage Portfolio Management owned 0.81% of CalciMedica worth $132,000 at the end of the most recent reporting period.

Separately, BML Capital Management LLC increased its position in CalciMedica by 63.8% in the 4th quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock valued at $416,000 after acquiring an additional 56,643 shares in the last quarter.

CalciMedica Stock Performance

CalciMedica stock opened at $5.45 on Friday. The business has a 50-day moving average of $4.31 and a 200-day moving average of $3.84. CalciMedica, Inc. has a 1 year low of $1.75 and a 1 year high of $8.59.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.77. On average, analysts anticipate that CalciMedica, Inc. will post -2.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CALC has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of CalciMedica in a research report on Monday, April 1st. Jonestrading initiated coverage on CalciMedica in a report on Friday, February 16th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Oppenheimer reissued an “outperform” rating and issued a $14.00 target price on shares of CalciMedica in a research note on Monday, April 1st.

About CalciMedica

CalciMedica, Inc, a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.